

Liver inflammation is common and linked to metabolic derangements in treated HIV

Kara W. Chew,¹ Kunling Wu,² Katherine Tassiopoulos,² Frank J. Palella, Jr.,³ Susanna Naggie,⁴ Netanya Utay,⁵ Edgar T. Overton,⁶ Mark Sulkowski⁷,

for the ACTG A5322 Study Team

¹David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, ²Harvard T.H. Chan School of Public Health, Boston, MA, USA, ³Northwestern University, Feinberg School of Medicine, Chicago, IL, USA, ⁴Duke University School of Medicine, Durham, NC, USA, ⁵University of Texas Health Science Center at Houston, Houston, TX, USA, ⁶University of Alabama School of Medicine, Birmingham, AL, USA, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, USA



Background and Objectives

- Abnormal serum liver enzymes in people with HIV (PWH) are common and frequently unexplained
- Nonalcoholic fatty liver disease (NAFLD) and drug toxicity are possible etiologies
- Previous studies suggest the prevalence of NAFLD is 13-67% in HIV cohorts and up to >70% amongst PWH who have unexplained transaminase elevation

Objectives:

- To determine the prevalence of and reasons for hepatic transaminase elevation in a cohort of adults with treated HIV without hepatitis B or C virus infection or heavy alcohol use

Study Design and Statistical Analysis

Study Design: Analysis of the longitudinal, observational AIDS Clinical Trials Group (ACTG) HAILO cohort (A5322)

- Prospectively, clinical outcomes, medications, plasma HIV-1 RNA, collected every 24 weeks; CD4 cell count, CBC, chemistries, LFTs, fasting blood glucose and lipids every 48 wks; HBV and HCV serologies every 96 weeks
- Self-administered survey of past 30 days of alcohol use every 48 weeks. Alcohol use defined as:
 - Binge = Men: >5+ drinks/2 hours; Women 4+/2 hours
 - Heavy = Men: >14 drinks/week; Women: >7; or bingeing
 - Moderate = Men: 7-14 drinks/week; Women: 3-7; no bingeing
 - Light = Men: <7 drinks/week; Women: <3/week; no bingeing
 - Abstainer = 0 drinks/week

Exclusion Criteria: Heavy alcohol use, anti-HCV Ab+, HBsAg+

Transaminase elevation defined as:

- Alanine aminotransferase (ALT) >30 U/L for men, >19 for women
- Aspartate aminotransferase (AST) >36 for men, >30 for women

Outcomes:

- ≥1 elevated AST or ALT during follow-up (PRIMARY)
- ≥2 consecutive elevated AST or ALT during follow-up
- No ALT or AST elevation

Hepatic Steatosis Index (HSI) = 8 x (ALT/AST ratio) + BMI (+2, if female; +2, if diabetes mellitus)

Metabolic Syndrome (MetS) = 3 or more of the following:

- Waist circumference >102cm for men or >88cm for women
- Blood pressure >130/85 or drug treatment for hypertension
- Fasting triglyceride level ≥150 mg/dL
- Fasting HDL <40 mg/dL (men) or <50 mg/dL (women)
- Fasting blood glucose ≥100 mg/dL or diabetes

NAFLD Fibrosis Score = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m²) + 1.13 × impaired fasting glucose/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×10⁹/L) - 0.66 × albumin (g/dl)

ASCVD risk score: Defined as in Goff et al, Circulation 2014

Statistical Analysis: Chi-square and Wilcoxon tests to compare characteristics between persons with and without elevated AST or ALT. Multiple logistic regression models included covariates with p<0.10 in univariate analysis.

Figure 1: Cohort Selection and AST/ALT Characterization





Table 1: Baseline Characteristics by AST/ALT Elevation

Characteristic (at entry)	No elevation (N=206)	≥1 elevation (N=456)	P-value
Age (years)	52 (47, 58)	50 (45, 56)	0.04*
Sex: Male	173 (84%)	351 (77%)	0.04**
Race/Ethnicity: White	114 (55%)	226 (50%)	0.03**
Black	62 (30%)	122 (27%)	
Hispanic	24 (12%)	92 (21%)	
Other	6 (3%)	10 (2%)	
Body mass index (kg/m ²)	26.9 (23.3, 30.9)	27.8 (24.7, 31.5)	0.01*
Waist circumference (cm)	96.3 (86.8, 104.9)	96.1 (89.6, 105.0)	0.15*
On lipid lowering meds: Yes	74 (36%)	208 (46%)	0.02**
Statins	49 (24%)	149 (33%)	--
Diabetes	15 (7%)	63 (14%)	0.02**
Hypertension treatment or BP >130/85	118 (57%)	273 (60%)	0.53**
Drinking Category: Abstainer	98 (48%)	208 (46%)	0.88**
Light Drinker	92 (45%)	213 (47%)	
Moderate Drinker	16 (8%)	35 (8%)	
Ever cocaine	164/205 (80%)	360/454 (79%)	0.71**
Smoking: Current	52 (25%)	81 (18%)	0.08**
Prior	61 (30%)	154 (34%)	
Never	93 (45%)	221 (48%)	
CD4 nadir (cells/mm ³)	191 (62, 287)	197 (67, 300)	0.70*
CD4 at entry (cells/mm ³)	589 (448, 803)	634 (470, 858)	0.04*
HIV RNA <200 copies/mL	196 (95%)	431 (95%)	0.74**
Current ARV regimen (yes/no)			
PI	70 (34%)	176 (39%)	0.26**
r/LPV	2	12	--
r/ATV	44	89	--
r/DRV	22	57	--
INSTI	48 (23%)	92 (20%)	0.36**
NNRTI	93 (45%)	209 (46%)	0.87**
Efavirenz	79	176	--
Ever d4T, AZT or ddI	78 (38%)	192 (42%)	0.30**
Ever PI	124 (60%)	307 (67%)	0.08**
Cumulative d4T or ddI exposure (years)	0 (0, 0)	0 (0, 0)	NS
Cumulative AZT (years)	0 (0, 2.2)	0 (0, 3.5)	0.17*
Years since ART initiation	7.80 (4.50, 11.90)	8.15 (4.60, 12.35)	0.48*
AST (U/L)	20 (17, 24)	26 (22, 33)	<0.001*
ALT (U/L)	19 (14, 23)	31 (22, 41)	<0.001*
Alkaline phosphatase (U/L)	77 (63, 99)	83 (67, 102)	0.03*
Platelets (x10 ⁹)	224 (196, 226)	227 (192, 266)	0.65*
Albumin (g/dL)	4.4 (4.2, 4.6)	4.5 (4.2, 4.7)	0.01**
Hemoglobin A1c (%)	5.5 (5.2, 5.8)	5.5 (5.3, 6.0)	0.09*
Estimated GFR by CKD-EPI	89 (74, 101)	92 (79, 104)	0.02*
Fasting cholesterol (mg/dL)	182 (163, 202)	190 (162, 216)	0.06*
Fasting triglycerides ≥150 mg/dL	62 (30%)	196 (43%)	<0.01**
Fasting HDL <40 (men) or <50 mg/dL (women)	57 (28%)	165 (36%)	0.03**
Fasting glucose ≥100 mg/dL or pre-diabetes	49 (24%)	146 (32%)	0.03**
Fasting LDL (mg/dL)	107 (89, 127)	109 (89, 130)	0.34*
Metabolic Syndrome	58 (28%)	164 (36%)	<0.05**
Hepatic Steatosis Index	34.72 (30.36, 39.04)	38.34 (34.36, 42.56)	<0.001*
<30	42 (20%)	37 (8%)	<0.001*
≥36	82 (40%)	300 (66%)	<0.001*
NAFLD Fibrosis Score	-1.646 (-2.454, -1.090)	-1.979 (-2.646, -1.199)	0.02*
<-1.455	121 (59%)	313 (69%)	0.01**
>0.675	7 (3%)	10 (2%)	0.36**
ASCVD Risk Score (%)	5.6 (3.1, 10.4)	4.7 (2.4, 8.9)	0.09*


No differences between groups in history of cocaine use or use of glucocorticoids, diabetes medications, antifungal therapy, NSAIDs, testosterone/anabolic steroids, progesterone/progestin, estrogen, acetaminophen. Similar findings restricting comparison to ≥2 consecutive elevated AST or ALT vs no elevation, with additional findings of lower frequency of r/PI use (p=0.030) and hypertension treatment or BP>130/85 (p=0.046), and greater cumulative AZT exposure (p=0.040) in the AST/ALT elevation group; metabolic differences were strengthened.

2A. Outcome: ≥1 AST or ALT elevation**



*Models also included race/ethnicity, prior vs never smoking, lipid lowering meds, hyperlipidemia, and alkaline phosphatase.

2B. Outcome: ≥2 AST or ALT elevations**



**Given collinearity, HSI and MetS were not included in the same model.

*Models also included entry CD4 cell count, prior vs never smoking

Conclusions

- Liver enzyme elevation in the absence of HCV infection, chronic HBV infection, or heavy alcohol use is very common (two-thirds by single elevation, one-third by two consecutive elevations) in this PWH cohort, suggesting a high rate of untreated liver injury/inflammation
- Transaminase elevation is associated with female sex, Hispanic ethnicity, higher CD4 and albumin levels, elevated triglycerides, and elevated blood pressure, consistent with findings from other studies of demographic and metabolic associations with NAFLD
- The CD4 association was lost with a stricter definition of AST/ALT elevation (2+ elevations), suggesting metabolic abnormalities are a stronger driver of liver disease development than HIV-related factors, but it is unknown if HIV-related variables (e.g. ART effects) may mediate metabolic dysregulation
- Higher Hepatic Steatosis Index was consistently associated with transaminase elevation, suggesting NAFLD may be a common cause of liver inflammation in PWH receiving suppressive ART
- The diagnosis of NAFLD in our cohort is limited given the absence of imaging or biopsy
- Future research is needed to understand the contribution of NAFLD and other mechanisms of liver injury in PWH on suppressive ART, and design interventions to reduce liver injury and liver-associated complications

Acknowledgements

We thank the study participants and sites.

Funding: NIAID UM1 AI068636 (ACTG) and UM1 AI01068634 (SDAC)

Contact Information:
Kara Chew MD, MS, UCLA Center for Clinical AIDS Research and Education
Email: kchew@mednet.ucla.edu